ZA846828B - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- ZA846828B ZA846828B ZA846828A ZA846828A ZA846828B ZA 846828 B ZA846828 B ZA 846828B ZA 846828 A ZA846828 A ZA 846828A ZA 846828 A ZA846828 A ZA 846828A ZA 846828 B ZA846828 B ZA 846828B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/12—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838323553A GB8323553D0 (en) | 1983-09-02 | 1983-09-02 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA846828B true ZA846828B (en) | 1985-07-31 |
Family
ID=10548231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA846828A ZA846828B (en) | 1983-09-02 | 1984-08-31 | Pharmaceutical compositions |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US4678786A (xx) |
| EP (1) | EP0138344A3 (xx) |
| JP (1) | JPS6089421A (xx) |
| AU (1) | AU3250884A (xx) |
| DK (1) | DK418684A (xx) |
| ES (1) | ES8601915A1 (xx) |
| GB (1) | GB8323553D0 (xx) |
| GR (1) | GR80223B (xx) |
| PT (1) | PT79152B (xx) |
| ZA (1) | ZA846828B (xx) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629254B2 (ja) * | 1986-09-08 | 1994-04-20 | 帝国臓器製薬株式会社 | ピリダジノン誘導体 |
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5536749A (en) * | 1994-10-13 | 1996-07-16 | Sl Pharmaceuticals, Inc. | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| JP4017214B2 (ja) | 1996-06-11 | 2007-12-05 | 興和創薬株式会社 | ５−フェニル−３−ピリダジノン誘導体 |
| DE19917603A1 (de) * | 1999-04-19 | 2000-10-26 | Inst Organische Katalyseforsch | Verfahren zur Desilylierung von 5-Alkoxy (bzw. 5-Aroxy)-3-trialkyl-silyl-2,3-dihydrofuran -2-onen |
| US20070060748A1 (en) * | 2002-11-27 | 2007-03-15 | Hamilton Gregory S | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| JP2008521806A (ja) * | 2004-11-30 | 2008-06-26 | アーテシアン セラピューティクス， インコーポレイテッド | 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物 |
| EP1833480A2 (en) * | 2004-11-30 | 2007-09-19 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| CA2658821C (en) | 2006-07-25 | 2014-10-21 | Cephalon, Inc. | Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors |
| US8106053B2 (en) | 2007-06-20 | 2012-01-31 | Kowa Company, Ltd. | 5-phenyl-3-pyridazinone derivative |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| PE20190472A1 (es) | 2016-04-15 | 2019-04-04 | Abbvie Inc | Inhibidores de bromodominios |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011321A (en) * | 1973-12-19 | 1977-03-08 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions and methods of inhibiting β-adrenergic receptors |
| GB1488330A (en) * | 1973-12-19 | 1977-10-12 | Smith Kline French Lab | Dihydropyridazinones |
| IE42214B1 (en) * | 1974-06-18 | 1980-07-02 | Smith Kline French Lab | Hydrazinopyredazines |
| GB1527712A (en) * | 1974-06-18 | 1978-10-11 | Smith Kline French Lab | Hydrazinopyridazines |
| US4111936A (en) * | 1974-06-18 | 1978-09-05 | Smith Kline & French Laboratories Limited | Pyridazinethiones |
| US4082843A (en) * | 1975-11-26 | 1978-04-04 | Smith Kline & French Laboratories Limited | 3-(3-(3-Substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines and their use as vasodilators and β-adrenergic blocking agents |
| US4397854A (en) * | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| IE54598B1 (en) * | 1981-11-12 | 1989-12-06 | Ici Plc | Pharmaceutically-active pyridylvinylpyridazinones |
| US4521416A (en) * | 1983-03-22 | 1985-06-04 | Warner-Lambert Company | 4,5-Dihydro-6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones and 6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones |
-
1983
- 1983-09-02 GB GB838323553A patent/GB8323553D0/en active Pending
-
1984
- 1984-08-28 GR GR80223A patent/GR80223B/el unknown
- 1984-08-29 EP EP84305870A patent/EP0138344A3/en not_active Withdrawn
- 1984-08-29 PT PT79152A patent/PT79152B/pt unknown
- 1984-08-29 AU AU32508/84A patent/AU3250884A/en not_active Abandoned
- 1984-08-31 ES ES535568A patent/ES8601915A1/es not_active Expired
- 1984-08-31 DK DK418684A patent/DK418684A/da not_active Application Discontinuation
- 1984-08-31 JP JP59183600A patent/JPS6089421A/ja active Pending
- 1984-08-31 ZA ZA846828A patent/ZA846828B/xx unknown
-
1986
- 1986-08-13 US US06/896,498 patent/US4678786A/en not_active Expired - Fee Related
-
1987
- 1987-03-20 US US07/028,375 patent/US4820819A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB8323553D0 (en) | 1983-10-05 |
| JPS6089421A (ja) | 1985-05-20 |
| GR80223B (en) | 1985-01-02 |
| ES535568A0 (es) | 1985-11-16 |
| US4678786A (en) | 1987-07-07 |
| EP0138344A2 (en) | 1985-04-24 |
| US4820819A (en) | 1989-04-11 |
| ES8601915A1 (es) | 1985-11-16 |
| DK418684D0 (da) | 1984-08-31 |
| PT79152A (en) | 1984-09-01 |
| EP0138344A3 (en) | 1986-01-15 |
| PT79152B (en) | 1986-11-14 |
| AU3250884A (en) | 1985-03-07 |
| DK418684A (da) | 1985-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2136807B (en) | Pharmaceutical compositions | |
| GB8423339D0 (en) | Pharmaceutical compositions | |
| DE3467703D1 (en) | Pharmaceutical compositions | |
| GB8313217D0 (en) | Pharmaceutical compositions | |
| GB8325494D0 (en) | Pharmaceutical compositions | |
| GB8415975D0 (en) | Pharmaceutical compositions | |
| GB8308126D0 (en) | Pharmaceutical compositions | |
| GR80444B (en) | Pharmaceutical compositions | |
| GB8427485D0 (en) | Pharmaceutical compositions | |
| GB2136806B (en) | Pharmaceutical compositions | |
| GB8317595D0 (en) | Pharmaceutical compositions | |
| CY1503A (en) | Pharmaceutical compositions | |
| GB8412569D0 (en) | Pharmaceutical compositions | |
| ZA846828B (en) | Pharmaceutical compositions | |
| GB8419243D0 (en) | Pharmaceutical compositions | |
| GB8305697D0 (en) | Pharmaceutical compositions | |
| GB8300767D0 (en) | Pharmaceutical compositions | |
| GB8416358D0 (en) | Pharmaceutical compositions | |
| GB8425250D0 (en) | Pharmaceutical compositions | |
| GB2150435B (en) | Pharmaceutical compositions | |
| GB8323623D0 (en) | Pharmaceutical compositions | |
| GB8331425D0 (en) | Pharmaceutical compositions | |
| GB8317469D0 (en) | Pharmaceutical compositions | |
| GB8300012D0 (en) | Pharmaceutical compositions | |
| GB8301718D0 (en) | Pharmaceutical compositions |